Checkpoint Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Checkpoint Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40,230	Closed	-$1.46M	–	7
2026 Q1	$1.46M	Buy	+40,230	New	+$1.8M	0.52%	7
2025 Q4	–	Sell	-260,000	Closed	-$10.8M	–	8
2025 Q3	$10.8M	Buy	+260,000	New	+$8.31M	3.63%	6

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Checkpoint Capital's CRNX Position: Q2 2026 in Review

Checkpoint Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 40,230 shares — an estimated $1.46M sold.

Checkpoint Capital first reported a position in CRNX in Q3 2025 and held it in 2 quarters. The position peaked at $10.8M in Q3 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Checkpoint Capital reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Checkpoint Capital sold 40,230 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.46M.
Checkpoint Capital first reported a position in Crinetics Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Checkpoint Capital's Crinetics Pharmaceuticals position peaked at $10.8M in Q3 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Checkpoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.